Despite the proven linearity of growth in the biotech sector and very high future potential, an area that requires attention is a Human Resource Development Facility for creating human resources specifically skilled in Biotech industry oriented molecular biology, bioprocess technology and bioanalytical sciences. Although there are more than 350 academic institutions in India teaching life sciences and biotechnology, the question often raised by the industry is how employable is this talent pool.
Thus there is a need to create finishing facilities either as separate entity or as a part of existing research institutes to make the talent pool directly employable in the Biopharmaceautical industry. Therefore, we have created an 'advanced learning school'. It has been identified that the human resource development for biotech/ life sciences need to be dealt with in two ways: Those having a flair for biopharmaceutical industry world should be given an appropriate learning opportunity, and at the same time, the research-oriented students should get ample support to help them in their pursuit. In this regard, the segregation seems to be one of the keys to address the problem of poor employability of the talent pool.
In light of this, we have established A National Facility for Biopharmaceuticals which will specifically address the human resource development. The Facility is designed and constructed strictly with international standards required for developing and manufacturing of recombinant Biopharmaceutical product. It would have GLP certification and ISO certifications required for the services it proposes to provide. The Facility has space and facilities for each student to excel in the area of Biotechnology / Bioprocess with hands on experience. The Facility would provide “third-party” evaluations of technology, products, processes and human resource in this highly competitive and sensitive field.
Aging populations and higher expectations are boosting demands for good medicines, and biologics now have a very successful track record. However, many biologics cost thousands - or even hundreds of thousands - of dollars. Biosimilars, by contrast, typically sell for between about 15% and 75% of the price of the original versions. So these are more affordable – in both mature economies with increasingly cash-strapped healthcare systems and emerging economies with increasingly affluent inhabitants. Biosimilars have considerable commercial potential, but exploiting that potential will not be easy. For one thing, biosimilars are much more difficult to develop and manufacture than traditional generics. The regulatory pathways for getting them approved are also less well established, and the competition – both from innovative companies and from rival biosimilars producers – is likely to be intense.
|Brand||Drug name||2009 Sales($bn)|
|Avonex i||nterferon beta-1a||2.32|
Challenge: Industry ready Human Resource Development The key challenge area that needs attention is skilled human resource required for production of these highly critical and complex biopharmaceuticals. Detailed survey of the academic institutes teaching life science and biotechnology in India shows that there are 380 private Biotech institutes, 120 Public Institutes with 1.12 lakh students per year.There is a need to create finishing facilities, either separate or as part of existing research or academic institutes. Therefore, we need ‘advanced learning schools’ for imparting scientific training to those students who wish to work directly in the industry after their post-graduation courses. In order to meet this challenge we propose to enhance, and leverage the equipment, infrastructure, and ability of the National Facility for Biopharmaceuticals for creating human resource ready, and employable for the industry.